Overview

Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris

Status:
Not yet recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Single Center, Double Blind, Placebo- Controlled Study of 20 subjects with 10 active drug/10 placebo Standardized baseline/pre-treatments and follow-up images will be taken. Subjects will receive injection of either study drug or placebo to the Depressor Anguli Oris. Follow ups will occur at 2 weeks, 4 weeks, and 12 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Amir Moradi MD, MBA
Collaborator:
Allergan
Treatments:
abobotulinumtoxinA
Botulinum Toxins, Type A